These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 12723945)

  • 21. Potent, selective, orally bioavailable inhibitors of tumor necrosis factor-alpha converting enzyme (TACE): discovery of indole, benzofuran, imidazopyridine and pyrazolopyridine P1' substituents.
    Lu Z; Ott GR; Anand R; Liu RQ; Covington MB; Vaddi K; Qian M; Newton RC; Christ DD; Trzaskos J; Duan JJ
    Bioorg Med Chem Lett; 2008 Mar; 18(6):1958-62. PubMed ID: 18282708
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis, preliminary biological evaluation and molecular modeling of some new heterocyclic inhibitors of TACE.
    Sengupta P; Puri CS; Chokshi HA; Sheth CK; Midha AS; Chitturi TR; Thennati R; Murumkar PR; Yadav MR
    Eur J Med Chem; 2011 Nov; 46(11):5549-55. PubMed ID: 21963348
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 1: Structure-based design of novel acetylenic P1' groups.
    Chen JM; Jin G; Sung A; Levin JI
    Bioorg Med Chem Lett; 2002 Apr; 12(8):1195-8. PubMed ID: 11934587
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Conversion of potent MMP inhibitors into selective TACE inhibitors.
    Cherney RJ; King BW; Gilmore JL; Liu RQ; Covington MB; Duan JJ; Decicco CP
    Bioorg Med Chem Lett; 2006 Feb; 16(4):1028-31. PubMed ID: 16289878
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hydantoins, triazolones, and imidazolones as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).
    Sheppeck JE; Gilmore JL; Tebben A; Xue CB; Liu RQ; Decicco CP; Duan JJ
    Bioorg Med Chem Lett; 2007 May; 17(10):2769-74. PubMed ID: 17368021
    [TBL] [Abstract][Full Text] [Related]  

  • 26. N-hydroxyformamide peptidomimetics as TACE/matrix metalloprotease inhibitors: oral activity via P1' isobutyl substitution.
    Musso DL; Andersen MW; Andrews RC; Austin R; Beaudet EJ; Becherer JD; Bubacz DG; Bickett DM; Chan JH; Conway JG; Cowan DJ; Gaul MD; Glennon KC; Hedeen KM; Lambert MH; Leesnitzer MA; McDougald DL; Mitchell JL; Moss ML; Rabinowitz MH; Rizzolio MC; Schaller LT; Stanford JB; Tippin T; Warner JR; Whitesell LG; Wiethe RW
    Bioorg Med Chem Lett; 2001 Aug; 11(16):2147-51. PubMed ID: 11514157
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of selective phosphonamide-based inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).
    Sawa M; Kurokawa K; Inoue Y; Kondo H; Yoshino K
    Bioorg Med Chem Lett; 2003 Jun; 13(12):2021-4. PubMed ID: 12781187
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acetylenic TACE inhibitors. Part 3: Thiomorpholine sulfonamide hydroxamates.
    Levin JI; Chen JM; Laakso LM; Du M; Schmid J; Xu W; Cummons T; Xu J; Jin G; Barone D; Skotnicki JS
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1605-9. PubMed ID: 16426848
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of novel hydroxamates as highly potent tumor necrosis factor-alpha converting enzyme inhibitors: Part I--discovery of two binding modes.
    Zhu Z; Mazzola R; Sinning L; McKittrick B; Niu X; Lundell D; Sun J; Orth P; Guo Z; Madison V; Ingram R; Beyer BM
    J Med Chem; 2008 Feb; 51(4):725-36. PubMed ID: 18247549
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis and biological activity of selective pipecolic acid-based TNF-alpha converting enzyme (TACE) inhibitors.
    Letavic MA; Axt MZ; Barberia JT; Carty TJ; Danley DE; Geoghegan KF; Halim NS; Hoth LR; Kamath AV; Laird ER; Lopresti-Morrow LL; McClure KF; Mitchell PG; Natarajan V; Noe MC; Pandit J; Reeves L; Schulte GK; Snow SL; Sweeney FJ; Tan DH; Yu CH
    Bioorg Med Chem Lett; 2002 May; 12(10):1387-90. PubMed ID: 11992783
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification and characterization of 4-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3S)thiomorpholinecarboxamide (TMI-1), a novel dual tumor necrosis factor-alpha-converting enzyme/matrix metalloprotease inhibitor for the treatment of rheumatoid arthritis.
    Zhang Y; Xu J; Levin J; Hegen M; Li G; Robertshaw H; Brennan F; Cummons T; Clarke D; Vansell N; Nickerson-Nutter C; Barone D; Mohler K; Black R; Skotnicki J; Gibbons J; Feldmann M; Frost P; Larsen G; Lin LL
    J Pharmacol Exp Ther; 2004 Apr; 309(1):348-55. PubMed ID: 14718605
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alpha,Beta-cyclic-beta-benzamido hydroxamic acids: Novel oxaspiro[4.4]nonane templates for the discovery of potent, selective, orally bioavailable inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).
    Ott GR; Asakawa N; Liu RQ; Covington MB; Qian M; Vaddi K; Newton RC; Trzaskos JM; Christ DD; Galya L; Scholz T; Marshall W; Duan JJ
    Bioorg Med Chem Lett; 2008 Feb; 18(4):1288-92. PubMed ID: 18234496
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The design and synthesis of aryl hydroxamic acid inhibitors of MMPs and TACE.
    Levin JI
    Curr Top Med Chem; 2004; 4(12):1289-310. PubMed ID: 15320727
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A new 4-(2-methylquinolin-4-ylmethyl)phenyl P1' group for the beta-amino hydroxamic acid derived TACE inhibitors.
    Chen XT; Ghavimi B; Corbett RL; Xue CB; Liu RQ; Covington MB; Qian M; Vaddi KG; Christ DD; Hartman KD; Ribadeneira MD; Trzaskos JM; Newton RC; Decicco CP; Duan JJ
    Bioorg Med Chem Lett; 2007 Apr; 17(7):1865-70. PubMed ID: 17276676
    [TBL] [Abstract][Full Text] [Related]  

  • 35. (E)-2(R)-[1(S)-(Hydroxycarbamoyl)-4-phenyl-3-butenyl]-2'-isobutyl-2'-(methanesulfonyl)-4-methylvalerohydrazide (Ro 32-7315), a selective and orally active inhibitor of tumor necrosis factor-alpha convertase.
    Beck G; Bottomley G; Bradshaw D; Brewster M; Broadhurst M; Devos R; Hill C; Johnson W; Kim HJ; Kirtland S; Kneer J; Lad N; Mackenzie R; Martin R; Nixon J; Price G; Rodwell A; Rose F; Tang JP; Walter DS; Wilson K; Worth E
    J Pharmacol Exp Ther; 2002 Jul; 302(1):390-6. PubMed ID: 12065742
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structure-activity relationship of hydroxamate-based inhibitors on membrane-bound Fas ligand and TNF-alpha processing.
    Yamamoto M; Hirayama R; Naruse K; Yoshino K; Shimada A; Inoue S; Kayagaki N; Yagita H; Okumura K; Ikeda S
    Drug Des Discov; 1999 Aug; 16(2):119-30. PubMed ID: 10533808
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acetylenic TACE inhibitors. Part 2: SAR of six-membered cyclic sulfonamide hydroxamates.
    Levin JI; Chen JM; Laakso LM; Du M; Du X; Venkatesan AM; Sandanayaka V; Zask A; Xu J; Xu W; Zhang Y; Skotnicki JS
    Bioorg Med Chem Lett; 2005 Oct; 15(19):4345-9. PubMed ID: 16084720
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis and biological activity of piperazine-based dual MMP-13 and TNF-alpha converting enzyme inhibitors.
    Letavic MA; Barberia JT; Carty TJ; Hardink JR; Liras J; Lopresti-Morrow LL; Mitchell PG; Noe MC; Reeves LM; Snow SL; Stam EJ; Sweeney FJ; Vaughn ML; Yu CH
    Bioorg Med Chem Lett; 2003 Oct; 13(19):3243-6. PubMed ID: 12951101
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New alpha-substituted succinate-based hydroxamic acids as TNFalpha convertase inhibitors.
    Barlaam B; Bird TG; Lambert-Van Der Brempt C; Campbell D; Foster SJ; Maciewicz R
    J Med Chem; 1999 Nov; 42(23):4890-908. PubMed ID: 10579851
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 2: lead optimization.
    Xue CB; He X; Roderick J; Corbett RL; Duan JJ; Liu RQ; Covington MB; Qian M; Ribadeneira MD; Vaddi K; Christ DD; Newton RC; Trzaskos JM; Magolda RL; Wexler RR; Decicco CP
    Bioorg Med Chem Lett; 2003 Dec; 13(24):4299-304. PubMed ID: 14643313
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.